Apogee Therapeutics (APGE) Gains from Investment Securities (2022 - 2026)
Apogee Therapeutics (APGE) reported Gains from Investment Securities of -$155000.0 for Q1 2026, down 115.52% year-over-year from $999000.0 in Q1 2025, and down 119.11% on a QoQ basis from $810997.0 in Q3 2025.
Apogee Therapeutics (APGE) has 5 years of Gains from Investment Securities data on file, last reported at -$155000.0 in Q1 2026.
- Quarterly Gains from Investment Securities fell 115.52% year-over-year to -$155000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (changed N/A YoY) and the FY2025 annual result came in at $5.6 million, up 8.83% from the prior year.
- Gains from Investment Securities eased to -$155000.0 in Q1 2026 per APGE's latest filing, from $810997.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $4.6 million in Q2 2023 and bottomed at -$155000.0 in Q1 2026.
- The 5-year median for Gains from Investment Securities is $904998.5 (2025), against an average of $1.3 million.
- The widest annual swing landed in 2025, when Gains from Investment Securities surged 2265.53%; it then sank 115.52% in 2026.
- Tracing APGE's Gains from Investment Securities over 5 years: stood at $2.8 million in 2022, then dropped by 9.34% to $2.5 million in 2023, then tumbled by 52.63% to $1.2 million in 2024, then sank by 31.68% to $810997.0 in 2025, then plunged by 119.11% to -$155000.0 in 2026.
- Per Business Quant, the three latest APGE Gains from Investment Securities figures stand at -$155000.0 (Q1 2026), $810997.0 (Q3 2025), and $77208.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Apogee Therapeutics | 5.53 Bn | 4.47 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -155,000.00 |
| Mar 31, 2026 | -155,000.00 |
| Sep 30, 2025 | 810,997.00 |
| Sep 30, 2025 | 810,997.00 |
| Jun 30, 2025 | 77,208.00 |
| Jun 30, 2025 | 77,208.00 |
| Mar 31, 2025 | 999,000.00 |
| Mar 31, 2025 | 999,000.00 |
| Dec 31, 2024 | 1.19 Mn |
| Dec 31, 2024 | 1.19 Mn |
| Sep 30, 2024 | 34,284.00 |
| Sep 30, 2024 | 34,284.00 |
| Jun 30, 2024 | 18,461.00 |
| Jun 30, 2024 | 18,461.00 |
| Mar 31, 2024 | 2.62 Mn |
| Mar 31, 2024 | 2.62 Mn |
| Dec 31, 2023 | 2.51 Mn |
| Dec 31, 2023 | 2.51 Mn |
| Sep 30, 2023 | 637,546.00 |
| Sep 30, 2023 | 637,546.00 |
| Jun 30, 2023 | 4.62 Mn |
| Jun 30, 2023 | 4.62 Mn |
| Dec 31, 2022 | 2.76 Mn |
| Dec 31, 2022 | 2.76 Mn |